Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_372661291399793de605ab00f27b329a |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12 |
filingDate |
2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0c9d62939c6512d82f8c9d67be7d11f |
publicationDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020237679-A1 |
titleOfInvention |
Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
abstract |
This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022035682-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020289459-A1 |
priorityDate |
2015-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |